NDA 022048 · Harrow Eye
Triesence
Triamcinolone Acetonide · Intravitreal · Corticosteroid
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 23, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Nov 29, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
692
135 Phase 3, 52 recruiting
FAERS reports
24,723
13,254 serious, 3,176 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 5, 2026.
TRIESENCE suspension is a synthetic corticosteroid indicated for: • Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. ( 1.1 ) • Visualization during vitrectomy. ( 1.2 ) 1.1 Ophthalmic Diseases TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for: • sympathetic ophthalmia, • temporal arteritis, • uveitis, and • ocular inflammatory conditions unresponsive to topical corticosteroids. 1.2 Visualization During Vitrectomy TRIESENCE suspension is indicated for visualization during vitrectomy.
Mechanism: Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisolone and triamcinolone are primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone acetonide possesses glucocorticoid activity typical of this class of drug, but with little or no mineralocorticoid activity. For the purposes of comparison, the following is the equivalent milligram dosage of the various glucocorticoids: Cortisone,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 29, 2007 Original approval · Type 3 - New Dosage Form · priority review LabelReviewPediatric Medical Review
1 products under this application
- TRIESENCE · TRIAMCINOLONE ACETONIDE 40MG/ML (40MG/ML) · INJECTABLE, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03568318 · 1,533 participants · Start Aug 9, 2018 · Primary completion Feb 16, 2021
Drug: Placebo; Upadacitinib and 1 more · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 193 sites in all
- Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel BlockagePivotal-lookingCompleted
National Eye Institute (NEI)NIH
NCT00106132 · 1,260 participants · Start Mar 2005
Drug: Triamcinolone Acetonide · For: Retinal Vein Occlusion; Macular Edema, Cystoid; Macular Edema
Sites: Bethesda, Maryland
- PRevention of Macular EDema After Cataract SurgeryPivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT01774474 · 1,127 participants · Start Jul 10, 2013 · Primary completion Nov 4, 2016
Drug: Bromfenac; Dexamethasone and 2 more · For: Cystoid Macular Edema; Cataract; Diabetes Mellitus
Sites: Vienna, Austria; Edegem, Belgium; Frankfurt am Main, Germany · 16 sites in all
- Lung Health Study IIPivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT00000569 · 1,116 participants · Start Sep 1993 · Primary completion May 1999
Drug: triamcinolone · For: Lung Diseases; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease
Suzan A RattanAcademic, hospital or other
NCT03634852 · 1,000 participants · Start Oct 1, 2016 · Primary completion Feb 1, 2018
Drug: Moxifloxacin hydrochloride 0.5% eye drops; Dexamethasone 0.1% eye drops and 2 more · For: Endophthalmitis Postoperative
- CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention TrialPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT00847912 · 954 participants · Start Jun 26, 2009 · Primary completion Jun 28, 2013
Drug: 5-fluorouracil; Placebo, vehicle control · For: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Skin Neoplasms and 4 more
Sites: Palo Alto, California; San Diego, California; Denver, Colorado · 13 sites in all
- Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular EdemaPivotal-lookingCompleted
Jaeb Center for Health ResearchAcademic, hospital or other
NCT00367133 · 840 participants · Start Jul 2004 · Primary completion May 2008
Drug: 1mg triamcinolone acetonide; 4mg triamcinolone acetonide · For: Diabetic Macular Edema
Sites: Little Rock, Arkansas; Baldwin Park, California; Beverly Hills, California · 84 sites in all
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02260986 · 740 participants · Start Sep 2014 · Primary completion Aug 2015
Drug: Dupilumab; Placebo (for Dupilumab) · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 148 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,844
- off label use2,908
- pruritus2,715
- rash2,561
- pain2,132
- fatigue2,036
- nausea1,946
- product use in unapproved indication1,748
- diarrhoea1,707
- vomiting1,703
- condition aggravated1,686
- headache1,626
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 71 |
| 2005 | 58 |
| 2006 | 40 |
| 2007 | 80 |
| 2008 | 116 |
| 2009 | 130 |
| 2010 | 119 |
| 2011 | 178 |
| 2012 | 185 |
| 2013 | 209 |
| 2014 | 260 |
| 2015 | 477 |
| 2016 | 646 |
| 2017 | 816 |
| 2018 | 1,065 |
| 2019 | 1,229 |
| 2020 | 1,486 |
| 2021 | 1,795 |
| 2022 | 2,317 |
| 2023 | 2,750 |
| 2024 | 3,546 |
| 2025 | 3,872 |
| 2026 | 3,278 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Resolved · updated Jul 31, 2026
Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ductal lavage followed by observation versus oral corticosteroids in idiopathic granulomatous mastitis: A randomized trial.
Chen X, Huang H, Huang H, et al. · Nat Commun 2024 · Comparative Study, Equivalence Trial
- Intralesional Triamcinolone Alone <em>Vs</em>. Combined Platelet-Rich Plasma for Keloid Treatment.
Afridi IK, Fiaz S, Wazir A, et al. · J Coll Physicians Surg Pak 2025 · Randomized Controlled Trial
- Efficacy of injectable platelet-rich fibrin in the treatment of symptomatic oral lichen planus.
Al-Hallak N, Hamadah O, Mouhamad M, et al. · Oral Dis 2023 · Randomized Controlled Trial
- Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata.
Abdallah MAE, Shareef R, Soltan MY · J Dermatolog Treat 2022 · Randomized Controlled Trial
- Botulinum toxin and platelet rich plasma as innovative therapeutic modalities for keloids.
Neinaa YME, Elsayed TA, Mohamed DA, et al. · Dermatol Ther 2021 · Randomized Controlled Trial
- Efficacy and clinical outcomes of suprachoroidal triamcinolone acetonide in diabetic macular edema patients: a single-arm systematic review and meta-analysis.
Karam M, Baeshen M, Abbas K, et al. · Graefes Arch Clin Exp Ophthalmol 2025 · Systematic Review, Meta-Analysis
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.